Could the New Federal Bill Derail the U.S. Hemp Industry?

A proposed spending bill in the House seeks to revise the legal definition of hemp, potentially banning hemp-derived cannabinoids like CBD and Delta-8 THC, impacting the $28.4 billion U.S. hemp industry; while an amendment clarified that industrial hemp and non-intoxicating products would be unaffected, ambiguity remains, raising concerns for companies like Canopy Growth, Curaleaf, and Tilray that have significant exposure to the hemp-derived products market, as the outcome could reshape cannabis reform and legalization efforts.

Analysis

A proposed U.S. House spending bill, introduced by Rep. Andy Harris, seeks to revise the legal definition of hemp established under the 2018 Farm Bill, targeting what is termed the "hemp loophole." This revision aims to cover all products "containing cannabinoids in any form" for human or animal use, potentially banning popular hemp-derived cannabinoids such as CBD, THCA, and Delta-8 THC at the federal level, should they be deemed intoxicating. This legislative action poses a significant threat to the U.S. hemp industry, valued by the National Cannabis Industry Association at $28.4 billion in 2023, as it could abruptly eliminate a substantial revenue stream for numerous companies. These companies have often built product lines around such compounds due to their higher margins, ease of distribution, and broad appeal, particularly in states without legal adult-use marijuana, thereby avoiding the heavier taxes and stricter regulations associated with marijuana. Despite a manager’s amendment adopted by the House Appropriations Committee, which clarified that the revision would not affect industrial hemp or non-intoxicating hemp-derived products, the actual legislative text remains unchanged, fueling industry concerns that the vague language could still be used to restrict widely sold items like CBD oils and full-spectrum extracts. Major cannabis companies, including Canopy Growth (CGC) through its Martha Stewart and Quatreau brands, Curaleaf Holdings (CURLF) via its Select brand, and Tilray Brands (TLRY) with its Manitoba Harvest label, have significant exposure to the hemp-derived products market. Their federally legal U.S. revenue streams, which benefit from fewer regulatory burdens than marijuana, now face considerable risk if the proposed redefinition moves forward, potentially reshaping the broader trajectory of cannabis reform and legalization efforts.

Key Decisions for Investors

• Investors should exercise significant caution with holdings in companies heavily reliant on revenues from hemp-derived cannabinoids, particularly CGC, CURLF, and TLRY, and closely monitor legislative developments regarding the proposed hemp redefinition.
• A thorough reassessment of portfolio exposure to the U.S. hemp market is warranted, specifically quantifying the revenue contribution from products such as CBD, THCA, and Delta-8 THC, which face potential federal prohibition under the new bill.
• Consider the broader implications of this legislative proposal as a potential bellwether for increased regulatory scrutiny across the entire cannabis sector, which could influence future investment sentiment and the path of federal cannabis reform.